# Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

> **NCT03315130** · PHASE2 · COMPLETED · sponsor: **Ra Pharmaceuticals** · enrollment: 45 (actual)

## Conditions studied

- Generalized Myasthenia Gravis

## Interventions

- **DRUG:** zilucoplan (RA101495)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03315130
- **Lead sponsor:** Ra Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-11
- **Primary completion:** 2018-12-10
- **Final completion:** 2020-11-19
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03315130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03315130, "Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03315130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*